Literature DB >> 9423789

Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease.

V R Arruda1, J M Annichino-Bizzacchi, M S Gonçalves, F F Costa.   

Abstract

The prothrombin gene variant resulting form a G-->A transition at position 20210 has been described as a common genetic risk factor for venous thrombosis. However, the risk for developing arterial disease is unknown. In this investigation, we studied 116 patients with venous thrombosis and 71 with arterial disease, all of whom were compared with 295 controls. Additionally, we also investigated the distribution of the prothrombin alleles among African descendents and Amazonian Indians from Brazil. The prevalence of 0.7% for 20210A allele in the control group increased to 4.3% (P = 0.021) among patients with venous thrombosis. There was also a high prevalence of the mutated allele in a selected arterial disease group (5.7%) without hyperlipoproteinemia, hypertension, and diabetes mellitus when compared to the controls (P = 0.013). Heterozygotes for the allele 20210A were common among individuals of African descent (2%) and rare among Indians. These data support the hypothesis that the prothrombin variant is a risk factor for venous thrombosis and suggest that it may also be a risk factor for arterial disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9423789

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  Prothrombin G20210A and factor V Leiden polymorphisms in stroke.

Authors:  Thierry Paluku They-They; Omar Battas; Ilham Slassi; Mohamed Abdou Rafai; Desire Tshala Katumbay; Sellama Nadifi
Journal:  J Mol Neurosci       Date:  2011-06-24       Impact factor: 3.444

2.  A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis.

Authors:  Wassim Y Almawi; Hala Tamim; Raghid Kreidy; Georgina Timson; Elias Rahal; Malak Nabulsi; Ramzi R Finan; Noha Irani-Hakime
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

Review 3.  Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype. A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David Bosler; Joan Mattson; Domnita Crisan
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

4.  Association of C677T MTHFR and G20210A FII prothrombin polymorphisms with susceptibility to myocardial infarction.

Authors:  Wiam Hmimech; Hind Hassani Idrissi; Brehima Diakite; Dalila Baghdadi; Farah Korchi; Rachida Habbal; Sellama Nadifi
Journal:  Biomed Rep       Date:  2016-07-13

5.  Prothrombin 20210G/A mutation in two patients with mesenteric ischemia.

Authors:  A Balian; A Veyradier; S Naveau; M Wolf; S Montembault; V Giraud; E Borotto; C Henry; D Meyer; J C Chaput
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

6.  Genetic thrombophilia in patients with retinal vascular occlusion.

Authors:  K Greiner; D Peetz; A Winkgen; W Prellwitz; N Pfeiffer; G Hafner
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

7.  Recurrent intra-cardiac thrombosis-A unique presentation of prothrombin G20210 mutation.

Authors:  Kartika Shetty; Nirmal Sunkara; Chowdhury Ahsan
Journal:  J Cardiol Cases       Date:  2011-03-09

8.  Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.

Authors:  Saurabh Singh Rathore; Surendra Kumar Agarwal; Shantanu Pande; Sushil Kumar Singh; Tulika Mittal; Balraj Mittal
Journal:  Indian J Clin Biochem       Date:  2011-05-01

9.  Elevated prothrombin promotes venous, but not arterial, thrombosis in mice.

Authors:  Maria M Aleman; Bethany L Walton; James R Byrnes; Jian-Guo Wang; Matthew J Heisler; Kellie R Machlus; Brian C Cooley; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

10.  Prothrombin gene G20210A mutation in acute deep venous thrombosis patients with poor response to warfarin therapy.

Authors:  F M Attia; D P Mikhailidis; S A Reffat
Journal:  Open Cardiovasc Med J       Date:  2009-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.